A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer
Launched by HOFFMANN-LA ROCHE · Jun 17, 2008
Trial Information
Current as of May 30, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • adult patients, \<=75 years of age;
- • chemotherapy-naive for stage IV colorectal cancer with unresectable liver metastasis;
- • \>=1 measurable lesion;
- • ECOG status 0-2.
- Exclusion Criteria:
- • prior exposure to Avastin;
- • clinical or radiological evidence of CNS metastases;
- • uncontrolled hypertension, or clinically significant cardiovascular disease;
- • ongoing treatment with aspirin (\>325mg/day) or other medications known to predispose to gastrointestinal ulceration.
About Hoffmann La Roche
Hoffmann-La Roche, commonly known as Roche, is a global leader in biotechnology and pharmaceuticals, committed to advancing healthcare through innovative research and development. With a strong focus on oncology, immunology, infectious diseases, and central nervous system disorders, Roche leverages cutting-edge science to deliver transformative therapies and diagnostics. The company is dedicated to improving patient outcomes by conducting rigorous clinical trials and collaborating with healthcare professionals and organizations worldwide. Roche's unwavering commitment to precision medicine and personalized healthcare positions it at the forefront of the industry, driving progress in the quest for effective treatments and improved patient care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Taipei, , Taiwan
Kaohsiung, , Taiwan
Taichung, , Taiwan
Taoyuan County, , Taiwan
Patients applied
Trial Officials
Clinical Trials
Study Director
Hoffmann-La Roche
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials